Skip to main content

New York Issues Clinical Laboratory Permit to Genetic Technologies

NEW YORK (GenomeWeb News) – Genetic Technologies today said that New York has issued a Clinical Laboratory Permit to the firm, allowing GTG to offer its BREVAGen test to residents of the state.

The permit completes the out-of-state licensures needed, and GTG can offer the breast cancer test to all 50 states in the US. GTG received CLIA certification of compliance for its Australian lab in February 2012.

Its wholly owned subsidiary Phenogen Sciences will soon appoint representatives to cover New York, with a particular emphasis on New York City, GTG said.

Earlier this week, the company said it received additional commitments for a private placement to raise A$800,000 and increased the level of underwriting on its current share purchase plan to A$1.8 million.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.